IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.
Brachytherapy, a form of radiation therapy where radioactive seeds – or isotopes – are placed near or inside the tumor to emit radiation, is one of the most intriguing both in the medical and investor community.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
Del Mar Pharmaceuticals was recently added to the roster of presenting companies at OneMedForum NY 2011.
Cancer, a word that strikes a chord of fear in many, is a fighting word. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry, and while it is a match we have yet to win, researchers and scientists have on their boxing gloves and are staying in the fight.
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
Copyright © 2025 | WordPress Theme by MH Themes